Leishmaniasis (Kala-Azar) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Leishmaniasis (Kala-Azar) is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms of Kala-Azar include weight loss, low blood counts, enlargement of the liver and spleen, and fever. Treatment includes anti-parasitic drugs.
The Leishmaniasis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Leishmaniasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Leishmaniasis and features dormant and discontinued projects.
Leishmaniasis Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Leishmaniasis pipeline drugs market are Ergosterol, Proteasome, 16S Ribosomal RNA, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, 30S Ribosomal Subunit, Casein Kinase 1 Isoform 2, Cell Membrane, DNA, and IkappaB Kinase among others. Ergosterol leads this segment of the Leishmaniasis pipeline drugs market.
Leishmaniasis Pipeline Drugs Market Analysis, by Targets
For more Leishmaniasis pipeline drugs market target insights, download a free report sample
Leishmaniasis Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Leishmaniasis pipeline drugs market are Ergosterol Inhibitor, Proteasome Inhibitor, 16S Ribosomal RNA Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, 30S Ribosomal Subunit Inhibitor, Casein Kinase 1 Isoform 2 Inhibitor, Cell Membrane Disruptor, and DNA Synthesis Inhibitor among others. Ergosterol Inhibitor leads the Leishmaniasis pipeline drugs market in terms of MoA.
Leishmaniasis Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Leishmaniasis pipeline drugs market, download a free report sample
Leishmaniasis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Leishmaniasis pipeline drugs market are oral, topical, intramuscular, and sublingual. Oral leads the Leishmaniasis pipeline drugs market in terms of RoA.
Leishmaniasis Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Leishmaniasis pipeline drugs market, download a free report sample
Leishmaniasis Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Leishmaniasis pipeline drugs market are Small Molecule, Live Attenuated Vaccine, Subunit Vaccine, Recombinant Vector Vaccine, Inactivated Vaccine, Oligonucleotide, and Recombinant Protein. Small Molecule leads the Leishmaniasis pipeline drugs market in terms of molecule types.
Leishmaniasis Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Leishmaniasis pipeline drugs market, download a free report sample
Leishmaniasis Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Leishmaniasis pipeline drugs market are Novartis AG, Appili Therapeutics Inc, Biokawthar Technologies SAS, BioLingus AG, Daiichi Sankyo Co Ltd, DetectoGen Inc, Eisai Co Ltd, GSK plc, Immune Modulation Inc, and Impetis Biosciences Ltd. Novartis AG has the highest number of products under development.
Leishmaniasis Pipeline Drugs Market Analysis, by Companies
To know more about the Leishmaniasis pipeline drugs market companies, download a free report sample
Leishmaniasis Pipeline Drugs Market Report Overview
Key Targets | Ergosterol, Proteasome, 16S Ribosomal RNA, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, 30S Ribosomal Subunit, Casein Kinase 1 Isoform 2, Cell Membrane, DNA, and IkappaB Kinase |
Key Mechanisms of Action | Ergosterol Inhibitor, Proteasome Inhibitor, 16S Ribosomal RNA Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, 30S Ribosomal Subunit Inhibitor, Casein Kinase 1 Isoform 2 Inhibitor, Cell Membrane Disruptor, and DNA Synthesis Inhibitor |
Key Routes of Administration | Oral, Topical, Intramuscular, and Sublingual |
Key Molecule Types | Small Molecule, Live Attenuated Vaccine, Subunit Vaccine, Recombinant Vector Vaccine, Inactivated Vaccine, Oligonucleotide, and Recombinant Protein |
Key Companies | Novartis AG, Appili Therapeutics Inc, Biokawthar Technologies SAS, BioLingus AG, Daiichi Sankyo Co Ltd, DetectoGen Inc, Eisai Co Ltd, GSK plc, Immune Modulation Inc, and Impetis Biosciences Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis.
- The pipeline guide reviews pipeline therapeutics for Leishmaniasis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leishmaniasis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leishmaniasis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Leishmaniasis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leishmaniasis.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Leishmaniasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Biokawthar Technologies SAS
BioLingus AG
Daiichi Sankyo Co Ltd
DetectoGen Inc
Eisai Co Ltd
GSK plc
Immune Modulation Inc
Impetis Biosciences Ltd
Macrophage Therapeutics Inc
ManRos Therapeutics
MedC Biopharma Ltd
Mind Medicine MindMed Inc
Molecular Targeting Technologies Inc
Mycosynthetix Inc
Nanomerics Ltd
Novartis AG
Oblita Therapeutics BVBA
Pai Life Sciences Inc
Pfizer Inc
Pharos iBio Co Ltd
Rakta Therapeutics Inc
Satellos Bioscience Inc
Synstar Japan Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Leishmaniasis pipeline drugs market?
Some of the targets of the Leishmaniasis pipeline drugs market are Ergosterol, Proteasome, 16S Ribosomal RNA, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, 30S Ribosomal Subunit, Casein Kinase 1 Isoform 2, Cell Membrane, DNA, and IkappaB Kinase among others.
-
What are the key mechanisms of action in the Leishmaniasis pipeline drugs market?
Some of the mechanisms of action of the Leishmaniasis pipeline drugs market are Ergosterol Inhibitor, Proteasome Inhibitor, 16S Ribosomal RNA Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, 30S Ribosomal Subunit Inhibitor, Casein Kinase 1 Isoform 2 Inhibitor, Cell Membrane Disruptor, and DNA Synthesis Inhibitor.
-
What are the key routes of administration in the Leishmaniasis pipeline drugs market?
The key routes of administration in the Leishmaniasis pipeline drugs market are oral, topical, intramuscular, and sublingual.
-
What are the key molecule types in the Leishmaniasis pipeline drugs market?
The molecule types in the Leishmaniasis pipeline drugs market are Small Molecule, Live Attenuated Vaccine, Subunit Vaccine, Recombinant Vector Vaccine, Inactivated Vaccine, Oligonucleotide, and Recombinant Protein.
-
Which are the leading companies in the Leishmaniasis pipeline drugs market?
Some of the leading companies in the Leishmaniasis pipeline drugs market are Novartis AG, Appili Therapeutics Inc, Biokawthar Technologies SAS, BioLingus AG, Daiichi Sankyo Co Ltd, DetectoGen Inc, Eisai Co Ltd, GSK plc, Immune Modulation Inc, and Impetis Biosciences Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.